Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Yingming Li, Rendong Yang, Christine Henzler, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 8, pp. 1965-1976
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Laura Cato, Jonas de Tribolet-Hardy, Irene Lee, et al.
Cancer Cell (2019) Vol. 35, Iss. 3, pp. 401-413.e6
Open Access | Times Cited: 158
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Cameron Herberts, Matti Annala, Joonatan Sipola, et al.
Nature (2022) Vol. 608, Iss. 7921, pp. 199-208
Closed Access | Times Cited: 119
Targeting the Androgen Signaling Axis in Prostate Cancer
Charles Dai, Scott M. Dehm, Nima Sharifi
Journal of Clinical Oncology (2023) Vol. 41, Iss. 26, pp. 4267-4278
Open Access | Times Cited: 61
Resistance to second-generation androgen receptor antagonists in prostate cancer
Keith T. Schmidt, Alwin D. R. Huitema, Cindy H. Chau, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 4, pp. 209-226
Closed Access | Times Cited: 86
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Matti Annala, Sinja Taavitsainen, Daniel Khalaf, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 16, pp. 4610-4623
Open Access | Times Cited: 75
Current and emerging therapies for neuroendocrine prostate cancer
Busola R. Alabi, Shiqin Liu, Tanya Stoyanova
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108255-108255
Closed Access | Times Cited: 41
Prostate cancer and liquid biopsies: Clinical applications and challenges
Fumihiko Urabe, Takayuki Sumiyoshi, Kojiro Tashiro, et al.
International Journal of Urology (2024) Vol. 31, Iss. 6, pp. 617-626
Open Access | Times Cited: 10
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
Jamie M. Sperger, Hamid Emamekhoo, Rana R. McKay, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 26, pp. 2926-2937
Open Access | Times Cited: 49
iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis
Jibin Guan, Hong Guo, Tang Tang, et al.
Advanced Functional Materials (2021) Vol. 31, Iss. 24
Open Access | Times Cited: 42
Androgen receptor mutations for precision medicine in prostate cancer
Masaki Shiota, Shusuke Akamatsu, Shigehiro Tsukahara, et al.
Endocrine Related Cancer (2022) Vol. 29, Iss. 10, pp. R143-R155
Open Access | Times Cited: 38
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer
Stephen Tang, Vidyalakshmi Sethunath, Nebiyou Y. Metaferia, et al.
Cell Reports (2022) Vol. 38, Iss. 8, pp. 110417-110417
Open Access | Times Cited: 31
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Jamie M. Sperger, Kyle T. Helzer, Charlotte N. Stahlfeld, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 12, pp. 2324-2335
Open Access | Times Cited: 20
Genomic Profiling of Prostate Cancer: An Updated Review
Koji Hatano, Norio Nonomura
The World Journal of Men s Health (2021) Vol. 40, Iss. 3, pp. 368-368
Open Access | Times Cited: 34
Stat5 induces androgen receptor ( AR ) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling
Cristina Maranto, Lavannya Sabharwal, Vindhya Udhane, et al.
Science Advances (2024) Vol. 10, Iss. 9
Open Access | Times Cited: 5
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Daisuke Obinata, Mitchell G. Lawrence, Ken‐ichi Takayama, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 34
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches
Mark P. Labrecque, Joshi J. Alumkal, Ilsa M. Coleman, et al.
Endocrine Related Cancer (2021) Vol. 28, Iss. 8, pp. T51-T66
Open Access | Times Cited: 32
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
Corinne Maurice‐Dror, Ronan Le Moigne, Ulka N. Vaishampayan, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 2, pp. 322-329
Closed Access | Times Cited: 29
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Adam G. Sowalsky, Ines Figueiredo, Rosina T. Lis, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 16, pp. 3509-3525
Open Access | Times Cited: 22
Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer
Qianhui Yi, Weiguo Liu, Jung Hwa Seo, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 5, pp. 570-582
Open Access | Times Cited: 11
Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer
Andrej Zivanovic, Jeffrey T. Miller, Sarah A. Munro, et al.
NAR Cancer (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 11
SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain
Qianhui Yi, Xiaojun Han, Henry Yu, et al.
Oncogene (2024) Vol. 43, Iss. 20, pp. 1522-1533
Closed Access | Times Cited: 4
Androgen receptor and estrogen receptor variants in prostate and breast cancers
José C. Valentín López, Carol A. Lange, Scott M. Dehm
The Journal of Steroid Biochemistry and Molecular Biology (2024) Vol. 241, pp. 106522-106522
Closed Access | Times Cited: 4
NGS-basierte („next generation sequencing“) molekulare Panelanalyse des metastasierten Prostatakarzinoms: Wie häufig finden wir therapierbare Mutationen?
Olivia Steenbock, Pia Paffenholz, Constantin Rieger, et al.
Deleted Journal (2025)
Open Access
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer
Yali He, Dong‐Jin Hwang, Suriyan Ponnusamy, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12642-12665
Open Access | Times Cited: 29
Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells
Jiaqian Liang, Liyang Wang, Larysa Poluben, et al.
Cancer Letters (2021) Vol. 519, pp. 172-184
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top